Evolus (EOLS) Stock: Buy, Sell, or Hold?
$7.42
+0.61 (+8.96%)
â˛
5d:
-0.67%
30d:
-1.2%
90d:
-7.48%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect EOLS Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (77%)
Quality Score
48/100
Position
FAIR
30-Day Fair Range
$7.07 â $7.62
Position: FAIR
Forward P/E & Valuation
24.3x
CHEAP
vs 28.6x historical avg
Wall Street Target
$15.40
+107.5% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$6.41 / $7.83
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: EOLS is fairly priced but lacks strong directional signals. At -5.3% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Get Alerted When EOLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.68
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.63
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EOLS is currently trading at $7.42, which is considered fair relative to its 30-day fair value range of $7.07 to $7.62. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.3) compared to its historical average (28.6). Remarkably, the market is currently pricing in an annual earnings decline of 5.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EOLS is in a strong downtrend. Immediate support is located at $6.41, while resistance sits at $7.83. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $15.40 (+107.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EOLS is in a strong downtrend. Immediate support is located at $6.41, while resistance sits at $7.83. The stock is showing strong short-term momentum, up 9.0% recently.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $15.40 (+107.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.07 -
$7.62
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Trading Range & Key Levels
30-Day Trading Range
$7.07 -
$7.62
Current vs Trading Range
FAIR
Support Level
$6.41
Resistance Level
$7.83
Current Trend
Strong Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding EOLS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.0%)
- BULLISH: Trading 107.5% below Wall St target ($15.40)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
24.33
Wall Street Target
$15.40
(+107.5%)
Revenue Growth (YoY)
13.0%
Profit Margin
-9.6%
Valuation Discount vs History
-5.3% cheaper
PE vs Historical
24.3 vs 28.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.3%
(market-implied from PE analysis)
1-Year Target
$7.03
(-5%)
2-Year Target
$6.65
(-10%)
3-Year Target
$6.30
(-15%)
3-Yr Target (if PE normalizes)
(PE: 24â29)
$7.41
(0%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.3 to 28.6
Stabilization Target:
$8.72
(+17.6%)
PE Expansion Potential:
+17.6%
Share EOLS Analysis
Share this live EOLS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (EOLS)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 9, 2026
Daily AI digest
AI Retail Discussion Summary:
StockTwits messages indicate bullish sentiment towards $EOLS with no new information from Yahoo Finance news.
Key Retail Themes:
Bullish sentiment
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:24 AM ET
Data refreshes hourly during market hours. Next update: 8:24 AM
Data refreshes hourly during market hours. Next update: 8:24 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EOLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$208 | 23 SELL |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$58 | 33 SELL |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$687 | 52 HOLD |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$63 | 53 HOLD |
Advanced EOLS Option Strategies
Professional options setups generated by AI based on today's EOLS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive EOLS Research Pages
